Aimmune Therapeutics, Inc.
If you purchased Aimmune Therapeutics, Inc. securities and would like to join the action, please click "Join This Action" below.
AIMMUNE MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF AIMMUNE THERAPEUTICS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM
August 31, 2020.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Aimmune Therapeutics, Inc. (NASDAQ: AIMT) to Sociétés des Produits Nestlé, S.A. (“Nestlé”) for $34.50 per share is fair to Aimmune shareholders. On behalf of Aimmune shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
The investigation concerns whether Aimmune and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible consideration for Aimmune shareholders; (2) determine whether Nestlé is underpaying for Aimmune; and (3) disclose all material information necessary for Aimmune shareholders to adequately assess and value the proposed transaction.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.